CEL-SCI Corporation operates as a biotechnology company. The Company engages in the research and development of immunotherapy products for the treatment of cancer, autoimmune, and infectious diseases. CEL-SCI offers its services across North America.

Current Report (Form 8-K | Period ending 2024-11-13)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

CEL-SCI (CVM US)

Current Report (Form 8-K | Period ending 2024-11-13)

Current Report (Form 8-K | Period ending 2024-11-12)

S-3/A | Registration statement for specified transactions by certain issuers (Amendment)

S-3 | Registration statement for specified transactions by certain issuers

S-3/A | Registration statement for specified transactions by certain issuers (Amendment)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)